SCHEMBL741192

SCHEMBL741192

O=Cc1ccccc1CC(F)(F)C(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
KMT2A Q03164 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
ALDH1A1 P00352 5/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.35
TRIM24 O15164 1/20 0.35
TRIM33 Q9UPN9 1/20 0.35
ERN1 O75460 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.31
GAA P10253 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
NPSR1 Q6W5P4 2/20 0.30
S1PR4 O95977 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7787987 0.82 ALDH1A1 (0.35) ALDH1A1
SCHEMBL8745969 0.81 LMNA (0.48) LMNAKMT2ATDP1MEN1THRB
SCHEMBL4088533 0.73 LMNA (0.48) LMNAKMT2ATDP1MEN1THRB
SCHEMBL2534011 0.71 ALDH1A1 (0.58) LMNAKMT2ATDP1MEN1THRB
SCHEMBL2680152 0.70 LMNA (0.55) LMNAKMT2ATDP1MEN1THRB
SCHEMBL7453987 0.69 LMNA (0.60) LMNAKMT2ATDP1MEN1THRB
SCHEMBL7788770 0.69 ALDH1A1 (0.37) ALDH1A1
SCHEMBL4893023 0.68 LMNA (0.46) LMNAKMT2ATDP1MEN1THRB
SCHEMBL30440526 0.68 TRIM24 (0.44) LMNAKMT2ATDP1MEN1THRB
SCHEMBL1199314 0.68 KMT2A (0.41) LMNAKMT2ATDP1MEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 EP disclosed
EP-2231160-B1 TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138219-B2 Tryptamine sulfonamides as 5-HT6 antagonists MERCK SHARP & DOHME CORP. (US) 2012-03-20 US disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 US disclosed
US-20100256106-A1 TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS MERCK & CO., INC. (US) 2010-10-07 US disclosed
EP-2231160-A1 TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2010-09-29 EP disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 US disclosed
WO-2009073118-A1 TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS MERCK & CO., INC. (US) 2009-06-11 WO disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 US disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256106-A1 TRYPTAMINE SULFONAMIDES AS 5-HT6 ANTAGONISTS HTR6, HTR4, HTR1A LMNA 3984/4885KMT2A 1984/4885TDP1 1745/4885
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B LMNA 4040/4885KMT2A 1269/4885TDP1 4272/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B LMNA 4040/4885KMT2A 1269/4885TDP1 4272/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B LMNA 4040/4885KMT2A 1269/4885TDP1 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.